Giuseppe Fornarini

List of Publications by Year
in descending order

102	2,007	257101	276539
papers	citations	24 h-index	41 g-index

105	105	105	3361
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa. Journal of Clinical Oncology, 2008, 26, 1619-1625.	0.8	161
2	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clinical Cancer Research, 2019, 25, 3839-3846.	3.2	147
3	Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. Journal of the National Cancer Institute, 2008, 100, 388-398.	3.0	123
4	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised â€˜GISCADâ€™ trial. Annals of Oncology, 2011, 22, 1236-1242.	0.6	98
5	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. European Urology, 2015, 68, 147-153.	0.9	73
6	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: realâ€world results from an expanded access programme. BJU International, 2019, 123, 98-105.	1.3	70
7	Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor. European Urology, 2006, 50, 1032-1039.	0.9	64
8	CDKN2Ais the main susceptibility gene in Italian pancreatic cancer families. Journal of Medical Genetics, 2012, 49, 164-170.	1.5	64
9	Primary mediastinal germ cell tumors. Seminars in Oncology, 2019, 46, 107-111.	0.8	49
10	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The â€˜GISCAD-alternating scheduleâ€™ study findings. European Journal of Cancer, 2009, 45, 65-73.	1.3	48
11	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 975-983.	1.1	43
12	First-Line PAzopanib in NOnâ€“clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clinical Genitourinary Cancer, 2017, 15, e609-e614.	0.9	42
13	First-line single-agent cetuximab in patients with advanced colorectal cancer. Annals of Oncology, 2008, 19, 711-716.	0.6	40
14	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy, 2018, 10, 1229-1239.	1.0	38
15	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	36
16	BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Research, 2000, 2, 307-10.	2.2	33
17	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Familial Cancer, 2012, 11, 41-47.	0.9	32
18	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or PoorÂPrognosis?. Clinical Genitourinary Cancer, 2018, 16, 355-359.e1.	0.9	31

#	Article	IF	Citations
19	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical Genitourinary Cancer, 2018, 16, e945-e951.	0.9	30
20	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e903-e908.	0.9	30
21	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clinical Genitourinary Cancer, 2019, 17, 291-298.	0.9	30
22	Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223. Cancers, 2020, 12, 31.	1.7	30
23	Plasma AR status and cabazitaxel in heavilyÂtreated metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 116, 158-168.	1.3	29
24	Predicting the Risk of Pancreatic Cancer: On CDKN2A Mutations in the Melanoma-Pancreatic Cancer Syndrome in Italy. Journal of Clinical Oncology, 2007, 25, 5336-5337.	0.8	26
25	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. Cancer, 2013, 119, 3429-3435.	2.0	26
26	Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Human Genetics, 2016, 135, 1241-1249.	1.8	24
27	The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer and Prostatic Diseases, 2021, 24, 1198-1207.	2.0	24
28	The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1063-1074.	3.3	24
29	Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis. Clinical Genitourinary Cancer, 2014, 12, 182-189.	0.9	23
30	Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncology, 2007, 3, 141-148.	1.1	22
31	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. Journal of Geriatric Oncology, 2014, 5, 156-163.	0.5	22
32	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	1.7	22
33	The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. Cancers, 2020, 12, 3213.	1.7	22
34	Cabozantinibâ€related cardiotoxicity: a prospective analysis in a realâ€world cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology, 2019, 85, 1283-1289.	1.1	21
35	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 42-45.	0.6	20
36	Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers, 2022, 14, 1245.	1.7	19

#	Article	IF	Citations
37	International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. Health and Quality of Life Outcomes, 2017, 15, 97.	1.0	18
38	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 140, 140-146.	1.3	18
39	Intra-Arterial Liver Chemotherapy and Hormone Therapy in Malignant Insulinoma: Case Report and Review of the Literature. Tumori, 2000, 86, 475-479.	0.6	16
40	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. Clinical Genitourinary Cancer, 2016, 14, e161-e169.	0.9	16
41	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy, 2020, 12, 151-159.	1.0	16
42	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). Frontiers in Oncology, 2021, 11, 682449.	1.3	16
43	Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Annals of Oncology, 2011, 22, 973-978.	0.6	15
44	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, 477-488.	0.9	15
45	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096846.	1.4	14
46	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4709.	1.8	13
47	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 121-125.	0.6	12
48	Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. World Journal of Gastroenterology, 2015, 21, 10688.	1.4	12
49	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.. Journal of Clinical Oncology, 2017, 35, 4521-4521.	0.8	11
50	Contrast-enhanced [18â€‰F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography. Cancer Imaging, 2014, 14, 10.	1.2	10
51	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e7-541.e13.	0.8	10
52	Enzalutamide in Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2018, 379, 1380-1381.	13.9	10
53	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. Oncologist, 2020, 25, e1509-e1515.	1.9	10
54	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210795.	1.4	10

#	Article	IF	Citations
55	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. Immunotherapy, 2018, 10, 1123-1132.	1.0	9
56	Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. Cancers, 2021, 13, 5517.	1.7	8
57	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. BMC Medicine, 2022, 20, 48.	2.3	8
58	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. Journal of Clinical Pathology, 2022, 75, 39-44.	1.0	7
59	Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. Cancers, 2022, 14, 1744.	1.7	7
60	Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy. Tumori, 2005, 91, 472-476.	0.6	6
61	Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake. Diagnostics, 2021, 11, 468.	1.3	6
62	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	1.7	6
63	Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223. Annals of Nuclear Medicine, 2022, 36, 373-383.	1.2	6
64	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. Critical Reviews in Oncology/Hematology, 2019, 137, 154-164.	2.0	5
65	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	0.8	5
66	Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program. European Journal of Preventive Cardiology, 2021, 28, e38-e40.	0.8	4
67	Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management. Diagnostics, 2022, 12, 581.	1.3	4
68	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers, 2022, 14, 2293.	1.7	4
69	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. Anticancer Research, 2018, 38, 4913-4918.	0.5	3
70	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 253-253.	0.8	3
71	Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).. Journal of Clinical Oncology, 2017, 35, 4577-4577.	0.8	3
72	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic Advances in Urology, 2021, 13, 175628722110543.	0.9	3

#	Article	IF	Citations
73	Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse event: a case report. Immunotherapy, 2021, 13, 1379-1386.	1.0	3
74	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	1.1	3
75	The handling of metastatic colorectal cancer. Annals of Oncology, 2005, 16, ii141-ii143.	0.6	2
76	Hepatosplenic T-cell Lymphoma with Aberrant Expression of Serum Î²-HCG: A Case Report. Tumori, 2015, 101, e160-e162.	0.6	2
77	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. Annals of Oncology, 2016, 27, vi252.	0.6	2
78	Functional analysis of a CDKN2A 5â€™UTR germline variant associated with pancreatic cancer development. PLoS ONE, 2017, 12, e0189123.	1.1	2
79	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 2018, 29, 705-709.	0.7	2
80	Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios. Immunotherapy, 2021, 13, 645-652.	1.0	2
81	First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.. Journal of Clinical Oncology, 2016, 34, e16081-e16081.	0.8	2
82	Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.. Journal of Clinical Oncology, 2018, 36, 209-209.	0.8	2
83	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World Journal of Clinical Oncology, 2021, 12, 1037-1046.	0.9	2
84	First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study. Annals of Oncology, 2016, 27, vi290.	0.6	1
85	Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP). Annals of Oncology, 2017, 28, v319-v320.	0.6	1
86	TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)â€"Liquid biopsy for biomarkers discovery.. Journal of Clinical Oncology, 2016, 34, TPS4584-TPS4584.	0.8	1
87	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A G.I.O.N. trial.. Journal of Clinical Oncology, 2017, 35, e16081-e16081.	0.8	1
88	Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer.. Journal of Clinical Oncology, 2012, 30, 411-411.	0.8	1
89	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 203-203.	0.8	1
90	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the â€˜Pameritâ€™ study. Japanese Journal of Clinical Oncology, 2021, 51, 484-491.	0.6	1

#	Article	IF	Citations
91	BRCA1 and BRCA2 Gene Mutations in Breast/Ovarian Cancer Patients from Central and Southern Italy. Disease Markers, 1999, 15, 96-96.	0.6	0
92	Prostate cancer screening with PSA: new data, old debate. Oncology Reviews, 2009, 3, 133-135.	0.8	0
93	First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study. Annals of Oncology, 2016, 27, iv32.	0.6	0
94	Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP). Annals of Oncology, 2017, 28, vi18.	0.6	0
95	Prospective evaluation of patients' preferences of three different regimens in a phase II study of FU, oxaliplatin, mitomycin C and CPT-11 in advanced colorectal cancer. Journal of Clinical Oncology, 2004, 22, 3757-3757.	0.8	0
96	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: Findings from the â€˜GISCAD-Alternating scheduleâ€™ study. Journal of Clinical Oncology, 2008, 26, 20502-20502.	0.8	0
97	Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study.. Journal of Clinical Oncology, 2010, 28, e14077-e14077.	0.8	0
98	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. Journal of Clinical Oncology, 2013, 31, 189-189.	0.8	0
99	Signs and genetics of rare cancer syndromes with gastroenterological features. World Journal of Gastroenterology, 2015, 21, 8985.	1.4	0
100	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2016, 34, TPS3629-TPS3629.	0.8	0
101	TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents.. Journal of Clinical Oncology, 2017, 35, TPS4601-TPS4601.	0.8	0
102	PAzopanib as first line in MEtastatic RCC patients: A â€œreal-worldâ€•Italian experience (PAMERIT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	0